このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Fase 3 Advanced EOC、Fallopianチューブ、または原発性腹膜がんの新たに診断された患者における標準NACTおよびアジュバント化学療法と組み合わせて投与されたIMNN-001の安全性と有効性を評価するフェーズ3試験 (OVATION-3)

2026年11月11日 更新者:Imunon

進行したEOC、卵管または原発性腹膜がんの新たに診断された患者における標準的なネオアジュバントおよび補助化学療法と組み合わせて投与されたIP IMNN-001の安全性と有効性を評価するランダム化第3相試験

This is a randomized, adaptive, open label, multicenter trial to evaluate the safety and efficacy of intraperitoneal (IP) IMNN-001 plus chemotherapy compared to chemotherapy alone.

調査の概要

状態

募集

条件

介入・治療

詳細な説明

Eligible participants will be randomly assigned 1:1 to receive either chemotherapy plus IMNN-001 or chemotherapy alone, followed by standard of care maintenance therapy.

Randomization will stratify by confirmed biomarker tumor homologous recombination deficiency status and stage of cancer.

On both arms, the chemotherapy regimen will consist of paclitaxel 175 mg/m2 IV over 3 hours followed by carboplatin AUC 6 IV over 1 hour on Day 1 of each cycle. This will be repeated every 3 weeks for a total of 6 cycles, 3 in the neoadjuvant period and 3 in the adjuvant period following interval debulking surgery (IDS). On the experimental arm, IMNN-001 at a dose of 100 mg/m2 will be administered IP on Days 8 and 15 of the first chemotherapy cycle and then on Days 1, 8, and 15 of all subsequent 5 chemotherapy cycles for a total of 17 treatments in the neoadjuvant and adjuvant settings. When given on the same day as chemotherapy, IMNN-001 should be given at least 30 minutes after completion of carboplatin infusion. IDS will take place after 3 cycles of neoadjuvant chemotherapy (NACT) + IMNN-001 for 8 doses. Additional cycles of NACT are allowed at the discretion of the investigator but with discussion with the medical monitor.

An independent Data Monitoring Committee (iDMC) will monitor participants' safety and study conduct throughout the course of the trial.

研究の種類

介入

入学 (推定)

500

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Douglas Faller, M.D.
  • 電話番号:+1 609 896 9100
  • メール:dfaller@imunon.com

研究連絡先のバックアップ

研究場所

    • Florida
      • Orlando、Florida、アメリカ、32804
    • Louisiana
      • New Orleans、Louisiana、アメリカ、70112
        • 募集
        • Louisiana State University HSC - NO Cancer Center
        • コンタクト:
        • 主任研究者:
          • Amelia Jernigan, M.D.
    • Michigan
      • Detroit、Michigan、アメリカ、48201
        • 募集
        • Karmanos Cancer Institute
        • コンタクト:
        • 主任研究者:
          • Robert Morris, M.D.
    • Minnesota
      • Minneapolis、Minnesota、アメリカ、55455
        • 募集
        • Masonic Cancer Center, University of Minnesota
        • コンタクト:
        • 主任研究者:
          • Melissa Geller, M.D.
    • Missouri
      • St Louis、Missouri、アメリカ、63110
        • 募集
        • Washington University School of Medicine in St. Louis
        • 主任研究者:
          • Andrea Hagemann, MD
        • コンタクト:
    • New York
      • Rochester、New York、アメリカ、14642
        • 募集
        • University of Rochester Medical Center
        • コンタクト:
          • Mckenzie McLoughlin
        • 主任研究者:
          • Richard Moore, M.D.
    • Oregon
      • Portland、Oregon、アメリカ、97213
        • 募集
        • Providence Cancer Institute
        • コンタクト:
        • 主任研究者:
          • Christopher Darus, MD
    • South Dakota
      • Sioux Falls、South Dakota、アメリカ、57104
    • Tennessee
    • Washington
      • Spokane、Washington、アメリカ、99204
        • 募集
        • Providence Sacred Heart Medical Center & Children's Hospital
        • 主任研究者:
          • Melanie Bergman, MD
        • コンタクト:
    • Wisconsin
      • Milwaukee、Wisconsin、アメリカ、53226
        • 募集
        • Froedtert and The Medical College of Wisconsin
        • 主任研究者:
          • William Bradley, MD
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

女性

説明

Inclusion Criteria:

  1. Participants must be female, ≥18 years of age, able to understand the study procedures, and agree to participate in the study by providing written informed consent.

  2. Participants with a histologically confirmed diagnosis of high-grade non-mucinous epithelial ovarian (serous, endometrioid, carcinosarcoma, mixed epithelial pathologies), fallopian tube or peritoneal cancer that is Stage IIIB/C or IV according to the International Federation of Gynecology and Obstetrics (FIGO) or tumor, node and metastasis staging criteria.

  3. Participants eligible to receive neoadjuvant chemotherapy.

  4. Participants will provide a tumor tissue sample at pre-screening or screening, via laparoscopy or image guided core biopsy for determination of confirmed biomarker tumor status (HRD vs. HRP). See biomarker status definitions in the section below.

  5. Participants of childbearing potential must have a negative serum pregnancy test (beta human chorionic gonadotropin) within 14 days prior to initiation of protocol therapy and be practicing an effective form of contraception. If applicable, participants must discontinue breastfeeding prior to study entry.

  6. Participants must have adequate:

    1. Bone marrow function: Absolute neutrophil count (ANC) greater than or equal to 1,500/µl. Exceptions may be made in patients with benign ethnic neutropenia >800/ul with approval of a medical monitor. This ANC cannot have been induced or supported by granulocyte colony stimulating factors. Platelets greater than or equal to 100,000/µl.
    2. Renal function: eGFR > 60 ml/min/1.73m2
    3. Hepatic function: Bilirubin ≤ 1.5 x ULN. SGOT (AST) and SGPT (ALT) ≤ 3.0 x ULN and alkaline phosphatase ≤ 2.5 x ULN. Exceptions due to hepatic metastases can be considered in consultation with medical monitor.
    4. Neurologic function: Neuropathy (sensory and motor) less than or equal to Grade 1 as defined by CTCAE version 5.0.
  7. Participants must have an ECOG score of 0, 1 or 2.

  8. Participants should be free of active infection requiring parenteral antibiotics or a serious uncontrolled medical illness or disorder within 4 weeks of study entry.

  9. Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to the first treatment. Continuation of hormone replacement therapy is permitted.

Exclusion Criteria:

  1. Participant who has received prior treatment with IMNN-001.
  2. Participant who has received oral or parenteral corticosteroids (>10 mg prednisone) within 2 weeks of first dose of IMNN-001 (if applicable) or who have a clinical requirement for ongoing systemic immunosuppressive therapy such as chronic steroid use not related to chemotherapy administration.
  3. Participant has mucinous, germ cell, transitional cell, clear cell, undifferentiated, or non-epithelial ovarian cancer.
  4. Participant has low-grade or Grade 1 epithelial ovarian cancer.
  5. Participant of childbearing potential, not practicing adequate contraception, participant who is pregnant, or participant who is breastfeeding are not eligible for this trial.
  6. Participant has a bowel obstruction by clinical symptoms or computed tomography (CT) scan, sub-occlusive mesenteric disease, abdominal or gastrointestinal fistula, gastrointestinal perforation, or intra-abdominal abscess.
  7. Participant has been diagnosed and/or treated with any therapy for invasive cancer <3 years from study enrollment, completed adjuvant chemotherapy and/or targeted therapy at least 3 years from enrollment, or completed adjuvant hormonal therapy less than 4 weeks from enrollment.
  8. Participant with definitively treated non-invasive malignancies such as cervical carcinoma in situ, ductal carcinoma in situ, grade 1 or 2 Stage IA endometrioid endometrial cancer, or non-melanomatous skin cancer are allowed.
  9. Participant with concurrent severe medical problems unrelated to the malignancy that would significantly limit full compliance with the study or expose the participant to extreme risk or decreased life expectancy.
  10. Participant has known active hepatitis or HIV with detectable viral load.
  11. Participant has a known contraindication or uncontrolled hypersensitivity to the components of paclitaxel, carboplatin, IMNN-001, or their excipients.
  12. Prior treatment for high-grade non-mucinous epithelial ovarian, fallopian tube, or peritoneal cancer (e.g., immunotherapy, anticancer therapy, surgery, radiation therapy).
  13. Participant is receiving treatment for active autoimmune disease. "Active" refers to any condition currently requiring therapy. Examples of autoimmune disease include systemic lupus erythematosus, multiple sclerosis, inflammatory bowel disease and rheumatoid arthritis.
  14. Participant who has received prior radiotherapy to any portion of the abdominal cavity or pelvis is excluded. Prior radiation for localized cancer of the breast, head and neck, or skin is permitted, if it was completed at least 3 years prior to registration, and the participant remains free of recurrent or metastatic disease.
  15. Participant who has received prior chemotherapy for any abdominal or pelvic tumor is excluded. Participant may have received prior adjuvant chemotherapy for localized breast cancer, if it was completed at least three years prior to registration, and that the participant remains free of recurrent or metastatic disease.
  16. Participant with history or evidence upon physical examination of CNS disease, including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months of the first date of treatment on this study.
  17. Participant who will receive bevacizumab with the neoadjuvant or adjuvant treatment, or as maintenance will be excluded.
  18. Participant with any condition/anomaly that would interfere with the appropriate placement of the IP catheter for study drug administration including abdominal surgery within 4 weeks of study entry (for reason other than IP port placement or laparoscopic diagnosis of epithelial ovarian cancer), intestinal dysfunction as defined in #6 above.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Experimental Arm: IMNN-001 + SOC Chemotherapy + SOC Maintenance Therapy

IMNN-001 in combination with standard neoadjuvant and adjuvant chemotherapy followed by standard of care maintenance therapy

100 mg/m2 IP given weekly during frontline treatment

他の名前:
  • GEN-1

175 mg/m2 IV given every 21 days for 6 cycles during frontline treatment

AUC 6 IV given every 21 days for 6 cycles during frontline treatment

Olaparib (300 mg orally every 12 hours for 2 years) for patients with somatic or germline BRCAmut.

他の名前:
  • リムパーザ

Niraparib (200-300 mg orally daily for 3 years; dosing based on participant's weight and platelet counts) for either HRD/BRCAmut & HRD/BRCAwt.

他の名前:
  • ゼジュラ
アクティブコンパレータ:Control Arm: SOC Chemotherapy + SOC Maintenance Therapy

Standard neoadjuvant and adjuvant chemotherapy followed by standard of care maintenance therapy.

175 mg/m2 IV given every 21 days for 6 cycles during frontline treatment

AUC 6 IV given every 21 days for 6 cycles during frontline treatment

Olaparib (300 mg orally every 12 hours for 2 years) for patients with somatic or germline BRCAmut.

他の名前:
  • リムパーザ

Niraparib (200-300 mg orally daily for 3 years; dosing based on participant's weight and platelet counts) for either HRD/BRCAmut & HRD/BRCAwt.

他の名前:
  • ゼジュラ

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Overall Survival
時間枠:48 months

Overall Survival is defined as the time (in months) from the date of randomization to the date of death by any cause.

48 months

二次結果の測定

結果測定
メジャーの説明
時間枠
Chemotherapy Response Score
時間枠:12 weeks

After the interval debulking surgery takes place, participants will be assessed for a chemotherapy response score by the pathologist and scored based on CRS3, CRS2, or CRS1.

12 weeks
Surgical Response
時間枠:12 weeks

After the interval debulking surgery takes place, participants are scored in terms of their interval debulking status with a score of R0, R1, or R2.

12 weeks
Time to Second Line Treatment
時間枠:13 months

Time to second line treatment is defined as the time (in months) from the date of randomization to the date of second line chemotherapy treatment or death, whichever occurs first.

13 months
Objective Response Rate
時間枠:12 weeks

Objective Response Rate is defined as the proportion of participants with objective evidence of CR or PR prior to IDS. The evaluation of objective response rate will be based on investigator (site) assessment of the images following RECIST v1.1 criteria.

12 weeks

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディチェア:Premal H Thaker, M.D.、Washington University School of Medicine

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年7月9日

一次修了 (推定)

2032年10月31日

研究の完了 (推定)

2032年10月31日

試験登録日

最初に提出

2025年4月1日

QC基準を満たした最初の提出物

2025年4月1日

最初の投稿 (実際)

2025年4月7日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月12日

QC基準を満たした最後の更新が送信されました

2026年11月11日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

キーワード

その他の研究ID番号

  • 201-24-301

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。